UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha]
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Seeking Alpha
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript UroGen Pharma Ltd. (NASDAQ: URGN Company Participants Kate Bechtold - IR Liz Barrett - President and CEO Mark Schoenberg - CMO Peter Pfreundschuh - CFO Conference Call Participants Derek Archila - Stifel Ram Selvaraju - H.C. Wainwright Boris Peaker - Cowen Matt Kaplan - Ladenburg Thalmann Chris Howerton - Jefferies Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to UroGen Pharma's First Quarter 2019 Financial Results and Business Update Conference Call. It is now my pleasure to turn the call over to Kate Bechtold, Director of Corporate Communications and Investor Relations for UroGen Pharma. Ple
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $22.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- UroGen Pharma Ltd. (NASDAQ: URGN) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $23.00 price target on the stock.MarketBeat
- UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers [Yahoo! Finance]Yahoo! Finance
- UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial CancersBusiness Wire
- UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at HC Wainwright from $64.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
URGN
Earnings
- 3/10/25 - Miss
URGN
Sec Filings
- 3/17/25 - Form SCHEDULE
- 3/10/25 - Form 10-K
- 3/10/25 - Form 8-K
- URGN's page on the SEC website